Cosmo Pharmaceuticals and Takeda Renew Multi-Year Manufacturing Agreement for Ulcerative Colitis Treatment
Key Insights
Cosmo Pharmaceuticals N.V. and Takeda (search) have renewed their multi-year manufacturing and supply agreement for Mesalazine MMX 1200 mg, an oral once-daily treatment for ulcerative colitis.
The agreement reinforces Cosmo's position as a trusted global manufacturing partner and aligns with the company's Vision 2030 strategy to expand CDMO leadership.
Production will continue at Cosmo's advanced 18,000 m² manufacturing facility in Lainate, Italy, which is approved by multiple regulatory authorities worldwide and ISO 13485 certified.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, announced the renewal of its multi-year manufacturing and supply agreement with Takeda (search) to produce Mesalazine MMX 1200 mg, marketed as Lialda® in the USA and Mezavant in Europe. The oral, once-daily treatment for ulcerative colitis represents a continuation of the companies' long-standing partnership in delivering critical gastrointestinal therapies to patients worldwide.
Strategic Partnership Reinforcement
"This renewal underscores our long-standing collaboration with Takeda (search) and our best-in-class manufacturing capabilities," said Giovanni Di Napoli, CEO of Cosmo. "We are proud of the trust our partners place in our R&D expertise and our ability to deliver high-quality pharmaceutical solutions. This agreement further strengthens our commitment to innovation, sustainability, and excellence, and it aligns perfectly with our Vision 2030 strategy to scale trusted partnerships and grow our CDMO leadership globally."
The renewed agreement positions Cosmo as a trusted partner for global production of key medicines, leveraging the company's established manufacturing expertise and regulatory compliance capabilities.
Advanced Manufacturing Capabilities
Production will continue at Cosmo's advanced manufacturing site in Lainate, Italy, which has been approved by multiple regulatory authorities worldwide. The facility has played a key role in supporting global pharmaceutical players for more than 30 years, ensuring efficient and environmentally responsible production with an excellent supply chain.
The 18,000 m² manufacturing site operates under a quality system certified in accordance with ISO 13485 standards, focusing on continuous improvement and customer satisfaction. This certification underscores the facility's commitment to maintaining the highest quality standards in pharmaceutical manufacturing.
Company Focus and Market Position
Cosmo Pharmaceuticals operates as a life sciences company with focus areas including MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures advanced solutions that address critical medical needs and raise the standard of care.
Founded in 1997 and headquartered in Dublin, Ireland, Cosmo maintains offices in San Diego, USA, and in Lainate, Rome, and Catania, Italy. The company's technologies are trusted by leading global pharmaceutical and MedTech companies, reaching patients and healthcare providers around the world through its mission to empower stakeholders by innovating at the intersection of science and technology.